(NP (NP (NNS Abnormalities)) (PP (IN of) (NP (NP-COOD (NP (NN p16)) (, ,) (NP (NN p15)) (CC and) (NP (NN CDK4))) (NNS genes))) (PP (IN in) (NP (JJ recurrent) (JJ malignant) (NNS astrocytomas))) (. .))
(S (NP-SBJ-38 (NP (NNS Abnormalities)) (PP (IN in) (NP (NP (DT the) (NP-COOD (NP (NN p16)) (, ,) (NP (NN p15)) (CC and) (NP (NN CDK4))) (NNS genes)) (SBAR (WHNP-39 (WDT that)) (S (NP-SBJ (-NONE- *T*-39)) (VP (VBP regulate) (NP (NP (NN transition)) (PP (IN through) (NP (NP (DT the) (NN G1) (NN phase)) (PP (IN of) (NP (DT the) (NN cell) (NN cycle)))))))))))) (VP (VBP have) (VP (VBN been) (VP (VBN implicated) (NP (-NONE- *-38)) (PP (IN in) (NP (NP (DT the) (JJ malignant) (NN progression)) (PP (IN of) (NP (NNS astrocytomas)))))))) (. .))
(S (NP-SBJ (NP (DT The) (NNS results)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (NP (NN dysfunction)) (PP (IN of) (NP (DT these) (NNS genes)))) (ADVP (RB also)) (VP (VBZ occurs) (PP-TMP (IN during) (NP (NP (NN recurrence)) (PP (IN of) (NP (NP (JJ glial) (NNS tumors)) (SBAR (WHNP-40 (WDT that)) (S (NP-SBJ (-NONE- *T*-40)) (VP (VBD were) (ADJP-PRD (RB highly) (JJ malignant)) (PP (IN at) (NP (JJ first) (NN presentation)))))))))))))) (. .))
(S (NP-SBJ (NP (NN Analysis)) (PP (IN of) (NP (NP (CD 10) (VBN matched) (NNS pairs)) (PP (IN of) (NP-COOD (NP (JJ high) (NN grade) (JJ malignant) (NNS astrocytomas)) (CC and) (NP (PRP$ their) (JJ subsequent) (NNS recurrences))))))) (VP (VBD identified) (NP (CD three) (JJ distinct) (NNS groups))) (. .))
(S-COOD (S (NP-SBJ (NP (DT The) (ADJP-COOD (ADJP (JJ primary)) (CC and) (ADJP (JJ recurrent))) (NNS tumors)) (PP (IN in) (NP (NN Group) (NN A)))) (VP (VBD did) (RB not) (VP (VB show) (NP (NP (JJ structural) (NNS alterations)) (PP (IN in) (NP (DT the) (NP-COOD (NP (NN p16)) (, ,) (NP (NN p15)) (CC or) (NP (NN CDK4))) (NNS genes))))))) (, ,) (IN whereas) (S (NP-SBJ-41 (NP (JJ homozygous) (NN codeletion)) (PP (IN of) (NP-COOD (NP (NN p16)) (CC and) (NP (NN p15))))) (VP (VBD was) (VP (VBN observed) (NP (-NONE- *-41)) (PP (IN in) (NP (NP (ADJP-COOD (CC both) (ADJP (JJ primary)) (CC and) (ADJP (JJ recurrent))) (NNS tumors)) (PP (IN in) (NP (NN Group) (NN B)))))))) (. .))
(S (NP-SBJ (NP (DT The) (JJ primary) (NNS tumors)) (PP (IN in) (NP (NN Group) (NN C)))) (VP (VBD had) (NP (NP (DT a) (JJ normal) (NN profile)) (PP (IN of) (NP-COOD (NP (NN p16)) (, ,) (NP (NN p15)) (CC and) (NP (NN CDK4))))) (PP (IN at) (NP (NN presentation)))) (. .))
(S (PP-TMP (IN Upon) (NP (NN recurrence))) (, ,) (ADVP (RB however)) (, ,) (NP-SBJ (DT the) (NNS tumors)) (VP (VBD sustained) (NP-COOD (CC either) (NP (NP (NN deletion)) (PP (IN of) (NP (NP (NN p16)) (ADVP (RB alone))))) (CC or) (NP (NP (NN codeletion)) (PP (IN of) (NP-COOD (CC both) (NP (NN p16)) (CC and) (NP (NN p15))))) (CC or) (NP (NP (NN amplification)) (PP (IN of) (NP (NN CDK4)))))) (. .))
(S (NP-SBJ (NP (NN Analysis)) (PP (IN of) (NP (NP (DT the) (JJ molecular) (NNS differences)) (PP (IN between) (NP-COOD (NP (JJ primary) (JJ anaplastic) (NNS (glioblastomas astrocytomas))) (CC and) (NP (PRP$ their) (JJ subsequent) (NNS recurrences)))) (, ,) (SBAR (WHNP-42 (WDT which)) (S (NP-SBJ (-NONE- *T*-42)) (VP (VBP are) (ADVP (RB clinically)) (ADJP-PRD (JJ indistinguishable))))) (, ,)))) (VP (MD may) (VP (VB provide) (NP (NP (JJR better) (JJ therapeutic) (NNS options)) (PP (IN for) (NP (NN treatment)))))) (. .))
